Lv4
668 积分 2024-03-20 加入
Antibody–Drug Conjugates in Uro-Oncology
18小时前
待确认
T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study
1个月前
已完结
T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study
1个月前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
2个月前
已完结
T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2个月前
已完结
T-cell-engaging bispecific antibodies in cancer
2个月前
已完结
ATB0,+-targeted nanoparticles initiate autophagy suppression to overcome chemoresistance for enhanced colorectal cancer therapy
5个月前
已完结
Formulation strategies to provide oxygen-release to contrast local hypoxia for transplanted islets
5个月前
已完结
TLRs induce Th1/Th2 responses by affecting the secretion of CCL2 at the maternal-foetal interface
7个月前
已完结
聚酰胺/聚醚酰亚胺复合纳滤膜的制备及其性能研究
8个月前
已采纳
皖公网安备34019202002308
